Maribavir

• CAT Number: I002293
• CAS Number: 176161-24-3
• Molecular Formula: C15H19Cl2N3O4
• Molecular Weight: 376.24
• Purity: ≥95%
• Target: CMV
• Solubility: DMSO: ≥ 51 mg/mL
• Storage: Store at -20°C
• InChI: InChI=1S/C15H19Cl2N3O4/c1-6(2)18-15-19-9-3-7(16)8(17)4-10(9)20(15)14-13(23)12(22)11(5-21)24-14/h3-4,6,11-14,21-23H,5H2,1-2H3,(H,18,19)/t11-,12-,13-,14-/m0/s1
• InChIKey: KJFBVJALEQWJBS-XUXIUFHCSA-N
• SMILES: O[C@@H]1[C@@H](N2C3=CC(Cl)=C(Cl)C=C3N=C2NC(C)C)O[C@@H](CO)[C@@H]1O

Maribavir (CAT: I002293) is a potent antiviral drug that belongs to the class of benzimidazole ribosides. It specifically targets and inhibits the UL97 protein kinase, which is essential for the replication of cytomegalovirus (CMV). Maribavir acts by disrupting viral DNA synthesis and preventing the phosphorylation of viral proteins necessary for CMV replication. As a result, it exhibits potent antiviral activity against CMV strains, including those that are resistant to other antiviral agents. Maribavir has been investigated for the treatment and prevention of CMV infections in immunocompromised patients, such as transplant recipients, where CMV reactivation can lead to serious complications.

Overview of Clinical Research

Originator: GlaxoSmithKline
Developer: Shire; ViroPharma
Class: Antivirals; Benzimidazoles; Ribonucleosides; Small molecules
Mechanism of Action: Ganciclovir-kinase-inhibitors
Orphan Drug Status: Yes – Cytomegalovirus infections
New Molecular Entity: Yes

Reference

1:Successful oral treatment of Ganciclovir resistant cytomegalovirus with Maribavir in the context of primary immunodeficiency: First case report and review. Bright PD, Gompels M, Donati M, Johnston S.J Clin Virol. 2017 Feb;87:12-16. doi: 10.1016/j.jcv.2016.12.006. Epub 2016 Dec 12. No abstract available. PMID: 27987421
2:Detection of Low Frequency Multi-Drug Resistance and Novel Putative Maribavir Resistance in Immunocompromised Pediatric Patients with Cytomegalovirus. Houldcroft CJ, Bryant JM, Depledge DP, Margetts BK, Simmonds J, Nicolaou S, Tutill HJ, Williams R, Worth AJ, Marks SD, Veys P, Whittaker E, Breuer J.Front Microbiol. 2016 Sep 9;7:1317. doi: 10.3389/fmicb.2016.01317. eCollection 2016. PMID: 27667983 Free PMC Article
3:In vitro studies of the impact of maribavir on CMV-specific cellular immune responses. Stachel D, Stevens-Ayers T, Boeckh M.J Clin Virol. 2016 Feb;75:53-9. doi: 10.1016/j.jcv.2015.12.012. Epub 2015 Dec 31. PMID: 26780109
4:Successful Use of Maribavir for Drug-resistant Cytomegalovirus Colitis in a Heart Transplant Recipient. Zegrí Reiriz I, Gómez-Bueno M, Segovia Cubero J.Rev Esp Cardiol (Engl Ed). 2015 Oct;68(10):908-9. doi: 10.1016/j.rec.2015.06.017. Epub 2015 Aug 22. No abstract available. PMID: 26304135
5:Suspicion of interaction between maribavir and everolimus in a renal transplant recipient. Verdier MC, Patrat-Delon S, Lemaitre F, Revest M, Rivalan J, Michelet C, Bellissant E.Transplantation. 2014 Aug 15;98(3):e20-1. doi: 10.1097/TP.0000000000000275. No abstract available. PMID: 25089341
6:Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility. Webel R, Hakki M, Prichard MN, Rawlinson WD, Marschall M, Chou S.J Virol. 2014 May;88(9):4776-85. doi: 10.1128/JVI.00192-14. Epub 2014 Feb 12. PMID: 24522923 Free PMC Article
7:Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection. Reitsma JM, Terhune SS.Antiviral Res. 2013 Nov;100(2):321-7. doi: 10.1016/j.antiviral.2013.09.011. Epub 2013 Sep 23. PMID: 24070820 Free PMC Article
8:Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient. Schubert A, Ehlert K, Schuler-Luettmann S, Gentner E, Mertens T, Michel D.BMC Infect Dis. 2013 Jul 19;13:330. doi: 10.1186/1471-2334-13-330. PMID: 23870704 Free PMC Article
9:Maribavir use in practice for cytomegalovirus infection in French transplantation centers. Alain S, Revest M, Veyer D, Essig M, Rerolles JP, Rawlinson W, Mengelle C, Huynh A, Kamar N, Garrigue I, Kaminski H, Segard C, Presne C, Mazeron MC, Avettant-Fenoël V, Lecuit M, Lortholary O, Coaquette A, Hantz S, Leruez-Ville M, Ploy MC.Transplant Proc. 2013 May;45(4):1603-7. doi: 10.1016/j.transproceed.2013.01.082. PMID: 23726629
10:Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase. Whitehurst CB, Sanders MK, Law M, Wang FZ, Xiong J, Dittmer DP, Pagano JS.J Virol. 2013 May;87(9):5311-5. doi: 10.1128/JVI.03505-12. Epub 2013 Feb 28. PMID: 23449792 Free PMC Article